Clonazepam
Schizophreniform Disorder
Palo Alto Veterans Institute for ResearchSmall moleculePhase 4 / ApprovedDormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Schizophreniform Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine Alkermes, Inc. | Phase 4 | A |
Raloxifene Iris Sommer | Phase 4 | A |
Dexmedetomidine BioXcel Therapeutics Inc | Phase 4 | A |
Acetylcysteine University of Maryland, Baltimore | Phase 4 | BBB |
Risperidone Northwell Health | Phase 4 | BBB |
View all 39 →
Same molecule, other indications
Clonazepam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →